In/IN
silico/NN
Identification/NN
of/IN
SFRP1/NN
as/IN
a/DT
Hypermethylated/JJ
Gene/NN
in/IN
Colorectal/JJ
Cancers/NNS
./.
====================
Aberrant/JJ
DNA/NN
methylation/NN
,/,
as/IN
an/DT
epigenetic/JJ
marker/NN
of/IN
cancer/NN
,/,
influences/VBZ
tumor/NN
development/NN
and/CC
progression/NN
./.
====================
We/PRP
downloaded/VBD
publicly/RB
available/JJ
DNA/NN
methylation/NN
and/CC
gene/NN
expression/NN
datasets/NNS
of/IN
matched/VBN
cancer/NN
and/CC
normal/JJ
pairs/NNS
from/IN
the/DT
Cancer/NN
Genome/NN
Atlas/NNS
Data/NNS
Portal/JJ
and/CC
performed/VBN
a/DT
systematic/JJ
computational/JJ
analysis/NN
./.
====================
This/DT
study/NN
has/VBZ
three/CD
aims/NNS
to/TO
screen/VB
genes/NNS
that/WDT
show/VBP
hypermethylation/NN
and/CC
downregulated/VBD
patterns/NNS
in/IN
colorectal/JJ
cancers/NNS
,/,
to/TO
identify/VB
differentially/RB
methylated/VBN
regions/NNS
in/IN
one/CD
of/IN
these/DT
genes/NNS
,/,
SFRP1/NN
,/,
and/CC
to/TO
test/VB
whether/IN
the/DT
SFRP/NN
genes/NNS
affect/VBP
survival/NN
or/CC
not/RB
./.
====================
Our/PRP$
results/NNS
show/VBP
that/IN
31/CD
hypermethylated/JJ
genes/NNS
had/VBD
a/DT
negative/JJ
correlation/NN
with/IN
gene/NN
expression/NN
./.
====================
Among/IN
them/PRP
,/,
SFRP1/NN
had/VBD
a/DT
differentially/RB
methylated/VBN
pattern/NN
at/IN
each/DT
methylation/NN
site/NN
./.
====================
We/PRP
also/RB
show/VBP
that/IN
SFRP1/NN
may/MD
be/VB
a/DT
potential/JJ
biomarker/NN
for/IN
colorectal/JJ
cancer/NN
survival/NN
./.
====================
The/DT
Encyclopedia/NN
of/IN
DNA/NN
Elements/NNS
(/(
ENCODE/NNP
)/)
project/VBP
,/,
launched/VBN
in/IN
2003/CD
by/IN
the/DT
US/NN
National/JJ
Human/JJ
Genome/NN
Research/NN
Institute/RB
(/(
NHGRI/NN
)/)
,/,
has/VBZ
accelerated/VBN
the/DT
study/NN
of/IN
various/JJ
aspects/NNS
of/IN
epigenetics/NNS
[/(
1/CD
]/)
,/,
among/IN
which/WDT
DNA/NN
methylation/NN
has/VBZ
been/VBN
one/CD
of/IN
the/DT
most/JJS
actively/RB
studied/VBN
areas/NNS
[/(
2/CD
]/)
./.
====================
DNA/NN
methylation/NN
refers/VBZ
to/TO
the/DT
chemical/JJ
conversion/NN
of/IN
a/DT
cytosine/NN
nucleotide/NN
in/IN
DNA/NN
to/TO
5-methylcytosine/JJ
by/IN
DNA/NN
methyltransferase/NN
./.
====================
This/DT
phenomenon/NN
usually/RB
takes/VBZ
place/NN
at/IN
the/DT
genomic/JJ
region/NN
where/WRB
a/DT
cytosine/JJ
is/VBZ
immediately/RB
followed/VBN
by/IN
a/DT
guanine/NN
and/CC
where/WRB
the/DT
dinucleotide/NN
is/VBZ
enriched/VBN
more/RBR
than/IN
expected/VBN
from/IN
the/DT
G/NN
+/JJ
C/NN
content/JJ
of/IN
the/DT
genome/NN
./.
====================
Such/JJ
CpG/NN
islands/NNS
(/(
CGIs/NNS
)/)
are/VBP
typically/RB
found/VBN
in/IN
the/DT
promoter/NN
region/NN
of/IN
a/DT
gene/NN
,/,
regulating/VBG
its/PRP$
expression/NN
[/(
3/CD
]/)
./.
====================
Tumor/NN
suppressor/NN
genes/NNS
(/(
TSGs/NNS
)/)
,/,
including/VBG
DNA/NN
repair/NN
genes/NNS
that/WDT
repair/NN
DNA/NN
mismatch/NN
during/IN
DNA/NN
replication/NN
,/,
maintain/VBP
the/DT
normal/JJ
activities/NNS
of/IN
cells/NNS
,/,
preventing/VBG
cancer/NN
development/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
their/PRP$
hypermethylation/NN
may/MD
repress/VB
their/PRP$
expression/NN
,/,
influencing/VBG
the/DT
development/NN
and/CC
growth/NN
of/IN
cancer/NN
cells/NNS
./.
====================
Moreover/RB
,/,
TSG/NN
expression/NN
may/MD
cause/VB
gene/NN
silencing/NN
through/IN
the/DT
hypermethylation/NN
of/IN
CGIs/NNS
,/,
and/CC
such/JJ
a/DT
paradigm/NN
opens/NNS
up/IN
a/DT
new/JJ
avenue/JJ
of/IN
cancer/NN
diagnosis/NN
and/CC
treatment/NN
based/VBN
on/IN
DNA/NN
methylation/NN
profiles/NNS
[/(
4/CD
]/)
./.
====================
In/IN
cancer/NN
cells/NNS
,/,
genes/NNS
that/WDT
play/VBP
important/JJ
roles/NNS
in/IN
cell/NN
growth/NN
and/CC
differentiation/NN
,/,
such/JJ
as/IN
TSG/NN
,/,
DNA/NN
repair/NN
genes/NNS
,/,
and/CC
apoptosis-related/JJ
genes/NNS
,/,
show/VBP
downregulation/NN
in/IN
expression/NN
due/IN
to/TO
hypermethylation/NN
in/IN
their/PRP$
promoter/NN
regions/NNS
./.
====================
For/IN
example/NN
,/,
the/DT
expression/NN
of/IN
p16/NN
,/,
a/DT
well-known/JJ
TSG/NN
,/,
is/VBZ
downregulated/VBN
due/JJ
to/TO
its/PRP$
promoter/NN
hypermethylation/NN
[/(
5/CD
]/)
,/,
and/CC
DNA/NN
repair/NN
genes/NNS
,/,
such/JJ
as/IN
BRCA1/NN
and/CC
hMLH1/NN
,/,
are/VBP
also/RB
hypermethylated/VBN
,/,
repressing/VBG
their/PRP$
gene/NN
expression/NN
[/(
6/CD
]/)
./.
====================
It/PRP
appears/VBZ
that/IN
hypermethylation/NN
profiles/NNS
in/IN
CGIs/NNS
may/MD
be/VB
useful/JJ
targets/NNS
for/IN
cancer/NN
treatment/NN
./.
====================
Some/DT
DNA/NN
methylation/NN
inhibitors/NNS
have/VBP
been/VBN
used/VBN
as/IN
anticancer/JJ
agents/NNS
,/,
paving/VBG
a/DT
new/JJ
avenue/NN
for/IN
the/DT
development/NN
of/IN
anticancer/JJ
therapeutics/NNS
[/(
7/CD
]/)
./.
====================
Gene/NN
expression/NN
profiles/NNS
have/VBP
been/VBN
used/VBN
in/IN
cancer/NN
diagnosis/NN
and/CC
prognosis/NN
,/,
but/CC
mRNA/NN
levels/NNS
usually/RB
fluctuate/JJ
temporally/RB
or/CC
are/VBP
greatly/RB
influenced/VBN
by/IN
environmental/JJ
cues/NNS
,/,
resulting/VBG
in/IN
unstable/JJ
diagnostic/JJ
sensitivity/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
DNA/NN
hypermethylation/NN
can/MD
show/VB
high/JJ
specificity/NN
and/CC
sensitivity/NN
in/IN
cancer/NN
diagnosis/NN
[/(
8/CD
]/)
./.
====================
Furthermore/RB
,/,
its/PRP$
molecular/JJ
diagnosis/NN
is/VBZ
gaining/VBG
more/RBR
and/CC
more/RBR
acceptance/NN
due/JJ
to/TO
its/PRP$
availability/NN
through/IN
real-time/JJ
and/CC
quantitative/JJ
blood/NN
testing/NN
[/(
9/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
surveyed/VBD
colon/NN
cancer/NN
data/NNS
to/TO
look/VB
for/IN
genes/NNS
that/WDT
show/VBP
hypermethylation/NN
,/,
and/CC
investigated/VBD
their/PRP$
effects/NNS
on/IN
patient/NN
survival/NN
./.
====================
Data/NNS
====================
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
,/,
launched/VBN
in/IN
2009/CD
,/,
aimed/VBD
to/TO
analyze/VB
the/DT
genomic/JJ
features/NNS
through/IN
sequencing/NN
of/IN
about/RB
30/CD
different/JJ
types/NNS
of/IN
cancers/NNS
./.
====================
We/PRP
downloaded/VBD
the/DT
microarray/NN
datasets/NNS
on/IN
gene/NN
expression/NN
and/CC
DNA/NN
methylation/NN
of/IN
colorectal/JJ
cancer/NN
and/CC
normal/JJ
samples/NNS
from/IN
the/DT
following/VBG
URL/NN
:/:
https/NNS
:/:
//tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm/JJ
(/(
the/DT
``/NN
Data/NNS
Type/NN
''/CD
field/NN
was/VBD
selected/VBN
as/IN
``/RB
Clinical/JJ
,/,
''/NNP
``/CD
DNA/NN
Methylation/NN
,/,
''/NNP
and/CC
``/FW
Expression-Genes/NNS
''/NNP
)/)
./.
====================
There/EX
were/VBD
12/CD
matched/VBN
cancer/normal/JJ
pairs/NNS
of/IN
both/DT
data/NNS
types/NNS
,/,
and/CC
these/DT
were/VBD
defined/VBN
as/IN
the/DT
discovery/NN
set/NN
./.
====================
The/DT
microarray/NN
platforms/NNS
were/VBD
UNC_AgilentG4502A_07_3/NN
and/CC
Illumina/NN
Infinium/NN
Human/JJ
DNA/NN
Methylation/NN
27/CD
(/(
Illumina/NN
,/,
San/NNP
Diego/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
for/IN
gene/NN
expression/NN
and/CC
DNA/NN
methylation/NN
,/,
respectively/RB
./.
====================
For/IN
the/DT
methylation/NN
data/NNS
,/,
the/DT
so-called/JJ
M-value/NN
was/VBD
calculated/VBN
as/IN
the/DT
log2/NN
ratio/NN
of/IN
the/DT
intensities/NNS
of/IN
the/DT
methylated/JJ
probe/NN
versus/CC
unmethylated/JJ
one/CD
,/,
and/CC
the/DT
beta-value/JJ
was/VBD
the/DT
ratio/NN
of/IN
the/DT
methylated/JJ
probe/NN
intensity/NN
and/CC
the/DT
overall/JJ
intensity/NN
,/,
either/CC
methylated/VBN
or/CC
unmethylated/JJ
[/(
9/CD
]/)
./.
====================
For/IN
the/DT
clinical/JJ
outcome/NN
analysis/NN
,/,
we/PRP
downloaded/VBD
an/DT
expanded/VBN
dataset/NN
from/IN
the/DT
URL/NN
,/,
totaling/VBG
524/CD
samples/NNS
(/(
202/CD
samples/NNS
on/IN
the/DT
Illumina/NN
Infinium/NN
Human/JJ
DNA/NN
Methylation27/NN
platform/VBP
and/CC
322/CD
samples/NNS
on/IN
the/DT
Illumina/NN
Infinium/NN
Human/JJ
DNA/NN
Methylation450/NN
platform/VBP
)/)
,/,
and/CC
419/CD
samples/NNS
with/IN
clinical/JJ
information/NN
were/VBD
used/VBN
in/IN
the/DT
survival/NN
analysis/NN
./.
====================
For/IN
these/DT
samples/NNS
,/,
we/PRP
downloaded/VBD
a/DT
text/JJ
file/JJ
on/IN
tumor/NN
stage/NN
,/,
last/JJ
contact/NN
days/NNS
,/,
and/CC
vital/JJ
status/NN
./.
====================
Identification/NN
of/IN
hypermethylated/JJ
and/CC
downregulated/VBD
genes/NNS
====================
The/DT
discovery/NN
dataset/NN
was/VBD
used/VBN
for/IN
gene/NN
selection/NN
./.
====================
Illumina/NN
Infinium/NN
Human/JJ
DNA/NN
Methylation27/NN
level/NN
2/CD
data/NNS
were/VBD
screened/VBN
for/IN
differentially/RB
methylated/VBN
regions/NNS
(/(
DMRs/NNS
)/)
,/,
where/WRB
the/DT
median/JJ
M/NN
of/IN
the/DT
tumor/NN
samples/NNS
was/VBD
greater/JJR
than/IN
+1/CD
and/CC
that/IN
of/IN
the/DT
matched/VBN
normal/JJ
samples/NNS
was/VBD
less/RBR
than/IN
-1/CD
[/(
9/CD
]/)
./.
====================
For/IN
each/DT
gene/NN
,/,
the/DT
mean/JJ
mRNA/NN
expression/NN
level/NN
in/IN
tumor/NN
samples/NNS
was/VBD
compared/VBN
to/TO
that/DT
in/IN
normal/JJ
samples/NNS
./.
====================
Genes/NNS
showing/VBG
at/IN
least/JJS
4-fold/RB
down-regulation/NN
were/VBD
selected/VBN
./.
====================
DAVID/NN
(/(
http/NN
:/:
//david.abcc.ncifcrf.gov//JJ
)/)
was/VBD
used/VBN
for/IN
the/DT
functional/JJ
annotation/NN
of/IN
the/DT
gene/NN
list/NN
./.
====================
Survival/NN
analysis/NN
====================
Survival/NN
analysis/NN
was/VBD
undertaken/VBN
with/IN
the/DT
survival/NN
package/NN
in/IN
R/NN
(/(
version/NN
2.13.0/CD
)/)
./.
====================
Survival/NN
time/NN
was/VBD
represented/VBN
by/IN
the/DT
days/NNS
since/IN
cancer/NN
diagnosis/NN
in/IN
the/DT
hospital/JJ
until/IN
the/DT
last/JJ
contact/NN
date/NN
./.
====================
The/DT
survival/NN
time/NN
of/IN
the/DT
patients/NNS
who/WP
were/VBD
still/RB
alive/JJ
at/IN
the/DT
last/JJ
contact/NN
date/NN
were/VBD
treated/VBN
as/IN
censored/JJ
./.
====================
Kaplan-Meier/NN
survival/NN
plot/NN
and/CC
Cox/NN
regression/NN
analysis/NN
were/VBD
also/RB
performed/VBN
with/IN
the/DT
survival/NN
package/NN
./.
====================
In/IN
order/NN
to/TO
partition/NN
patients/NNS
into/IN
two/CD
groups/NNS
according/VBG
to/TO
methylation/NN
level/NN
,/,
the/DT
cutoff/JJ
point/NN
was/VBD
determined/VBN
by/IN
the/DT
maximally/RB
selected/VBN
rank/VBP
statistics/NNS
method/NN
,/,
available/JJ
in/IN
the/DT
R/NN
maxstat/NN
package/NN
./.
====================
Hypermethylated/JJ
and/CC
downregulated/VBD
genes/NNS
in/IN
colorectal/JJ
cancer/NN
====================
We/PRP
used/VBD
the/DT
discovery/NN
set/NN
(/(
12/CD
pairs/NNS
of/IN
colorectal/JJ
tumor/NN
and/CC
matched/VBN
normal/JJ
samples/NNS
)/)
to/TO
survey/VB
genes/NNS
showing/VBG
correlating/VBG
differential/JJ
DNA/NN
methylation/NN
and/CC
differential/JJ
gene/NN
expression/NN
./.
====================
All/DT
methylation/NN
probes/NNS
(/(
n/NN
=/JJ
27,578/CD
)/)
were/VBD
annotated/VBN
by/IN
the/DT
name/NN
of/IN
the/DT
neighboring/JJ
gene/NN
and/CC
were/VBD
matched/VBN
to/TO
the/DT
gene/NN
expression/NN
matrix/NN
./.
====================
In/IN
order/NN
to/TO
look/VB
for/IN
the/DT
probes/NNS
that/IN
were/VBD
specifically/RB
hypermethylated/VBN
only/RB
in/IN
tumors/NNS
,/,
we/PRP
used/VBD
the/DT
M-value/NN
of/IN
the/DT
methylation/NN
data/NNS
;/:
the/DT
median/JJ
M/NN
of/IN
tumors/NNS
(/(
n/NN
=/JJ
12/CD
)/)
was/VBD
greater/JJR
than/IN
1/CD
,/,
while/IN
the/DT
matched/VBN
normal/JJ
samples/NNS
(/(
n/NN
=/JJ
12/CD
)/)
had/VBD
a/DT
median/JJ
M/NN
of/IN
less/RBR
than/IN
-1/CD
./.
====================
There/EX
were/VBD
634/CD
such/JJ
probes/NNS
./.
====================
We/PRP
also/RB
identified/VBD
707/CD
genes/NNS
showing/VBG
more/RBR
than/IN
4-fold/JJ
downregulation/NN
in/IN
tumor/NN
samples/NNS
compared/VBN
to/TO
their/PRP$
matched/VBN
normal/JJ
samples/NNS
./.
====================
There/EX
were/VBD
31/CD
genes/NNS
that/WDT
were/VBD
shared/VBN
by/IN
those/DT
two/CD
lists/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Fig/NN
./.
====================
1/CD
shows/VBZ
the/DT
scatterplot/NN
of/IN
the/DT
mean/JJ
differential/JJ
methylation/NN
versus/CC
mean/NN
differential/JJ
expression/NN
of/IN
these/DT
31/CD
genes/NNS
(/(
red/JJ
points/NNS
)/)
on/IN
the/DT
background/NN
of/IN
27,578/CD
methylation/NN
probes/NNS
(/(
grey/PRP
points/NNS
)/)
./.
====================
At/IN
the/DT
sample/NN
level/NN
,/,
these/DT
31/CD
genes/NNS
showed/VBD
a/DT
negative/JJ
correlation/NN
between/IN
methylation/NN
and/CC
expression/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Gene/NN
ontology/NN
and/CC
pathway/NN
analysis/NN
====================
Gene/NN
ontology/NN
analysis/NN
using/VBG
DAVID/NN
revealed/VBD
that/IN
the/DT
31/CD
genes/NNS
were/VBD
enriched/VBN
in/IN
the/DT
Wnt/NN
receptor/NN
signaling/NN
pathway/NN
(/(
Fisher/RB
exact/JJ
=/JJ
9.6E-5/CD
)/)
;/:
4/CD
genes-RSPO2/NN
,/,
RSPO3/NN
,/,
SFRP1/NN
,/,
and/CC
SFRP2-belonged/JJ
to/TO
this/DT
pathway/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Site/NN
of/IN
Frizzled/JJ
proteins/NNS
(/(
SFRP/NN
)/)
genes/NNS
interact/VBP
directly/RB
with/IN
Wnt/NN
,/,
the/DT
ligand/NN
of/IN
the/DT
Wnt/NN
signaling/NN
pathway/NN
Frizzled/JJ
(/(
Fz/NN
)/)
receptor/NN
,/,
inhibiting/VBG
the/DT
binding/NN
of/IN
Wnt/NN
to/TO
Fz/NN
receptor/NN
[/(
10/CD
]/)
./.
====================
The/DT
Kyoto/JJ
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
pathway/NN
diagram/NN
(/(
http/NN
:/:
//www.genome.jp/kegg//JJ
)/)
also/RB
confirmed/VBD
that/IN
Wnt/NN
and/CC
SFRP/NN
regulate/VBP
the/DT
Wnt/NN
signaling/NN
pathway/NN
at/IN
the/DT
upstream/JJ
level/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Wnt/NN
signaling/NN
pathway-related/JJ
genes/NNS
in/IN
colorectal/JJ
cancer/NN
====================
Both/DT
the/DT
SFRP1/NN
and/CC
SFRP2/NN
genes/NNS
are/VBP
known/VBN
to/TO
show/VB
DNA/NN
hypermethylation/NN
in/IN
colorectal/JJ
cancers/NNS
;/:
their/PRP$
relatively/RB
low/JJ
expression/NN
causes/VBZ
upregulation/NN
of/IN
Wnt/NN
signaling/NN
and/CC
thus/RB
tumor/NN
cell/NN
proliferation/NN
[/(
11/CD
]/)
./.
====================
Wnt2/NN
,/,
a/DT
member/NN
of/IN
the/DT
Wnt/NN
gene/NN
family/NN
,/,
and/CC
SFRP1/NN
showed/VBD
drastically/RB
opposite/JJ
gene/NN
expression/NN
patterns/NNS
in/IN
the/DT
discovery/NN
dataset/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
Given/IN
the/DT
premise/JJ
that/DT
downregulation/NN
of/IN
SFRP1/NN
and/CC
SFRP2/NN
due/JJ
to/TO
DNA/NN
hypermethylation/NN
deteriorates/VBZ
the/DT
inhibition/NN
of/IN
the/DT
Wnt/NN
ligand/NN
signaling/NN
pathway/NN
,/,
we/PRP
surveyed/VBD
the/DT
gene/NN
expression/NN
profile/NN
of/IN
the/DT
pathway/NN
genes/NNS
,/,
including/VBG
SFRP/NN
./.
====================
The/DT
significance/NN
of/IN
the/DT
differential/JJ
expression/NN
of/IN
each/DT
gene/NN
was/VBD
measured/VBN
by/IN
t/NN
test/NN
using/VBG
the/DT
discovery/NN
dataset/NN
./.
====================
The/DT
p-value/JJ
distributions/NNS
were/VBD
compared/VBN
between/IN
the/DT
genes/NNS
involved/VBN
in/IN
Wnt/NN
signaling/NN
(/(
n/NN
=/JJ
151/CD
)/)
and/CC
those/DT
that/DT
were/VBD
not/RB
involved/VBN
in/IN
Wnt/NN
signaling/NN
(/(
n/NN
=/JJ
17,658/CD
)/)
using/VBG
Wilcoxon/JJ
rank-sum/NN
test/NN
./.
====================
The/DT
genes/NNS
involved/VBN
in/IN
Wnt/NN
signaling/NN
showed/VBD
more/RBR
significant/JJ
differential/JJ
expression/NN
than/IN
the/DT
others/NNS
(/(
p/NN
=/JJ
0.01658/CD
)/)
./.
====================
SFRP1/NN
and/CC
WNT2/NN
were/VBD
among/IN
the/DT
top/NN
ranked/VBD
genes/NNS
of/IN
the/DT
pathway/NN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
DMR/NN
of/IN
SFRP1/NN
gene/NN
in/IN
colorectal/JJ
cancer/NN
====================
Illumina/NN
Human/JJ
DNA/NN
Methylation27/NN
and/CC
450/CD
are/VBP
microarray/NN
platforms/NNS
that/DT
can/MD
measure/VB
the/DT
methylation/NN
values/NNS
of/IN
promoter/NN
regions/NNS
,/,
with/IN
27,578/CD
and/CC
331,182/CD
probes/NNS
,/,
respectively/RB
./.
====================
On/IN
the/DT
former/JJ
platform/NN
,/,
there/EX
are/VBP
four/CD
probes/NNS
in/IN
the/DT
promoter/NN
region/NN
of/IN
SFRP1/NN
,/,
and/CC
their/PRP$
methylation/NN
status/NN
varies/VBZ
probe/NN
to/TO
probe/VB
,/,
while/IN
the/DT
latter/JJ
has/VBZ
33/CD
additional/JJ
probes/NNS
for/IN
SFRP1/NN
./.
====================
We/PRP
examined/VBD
which/WDT
probes/NNS
showed/VBD
hypermethylation/NN
and/CC
correlated/VBD
with/IN
expression/NN
change/NN
using/VBG
the/DT
expanded/VBN
dataset/NN
,/,
for/IN
which/WDT
both/CC
data/NNS
types/NNS
were/VBD
available/JJ
(/(
n/NN
=/JJ
203/CD
)/)
./.
====================
Among/IN
the/DT
four/CD
SFRP1/NN
probes/NNS
that/DT
were/VBD
shared/VBN
between/IN
the/DT
two/CD
platforms/NNS
,/,
one/CD
of/IN
them/PRP
(/(
cg06166767/NN
,/,
chr8:41287005/NN
)/)
did/VBD
not/RB
show/VB
hypermethylation/NN
,/,
while/IN
the/DT
other/JJ
three/CD
showed/VBD
similar/JJ
hypermethylation/NN
(/(
Fig/NN
./.
====================
6/CD
)/)
./.
====================
Table/JJ
3/CD
shows/VBZ
the/DT
correlation/NN
between/IN
differential/JJ
methylation/NN
and/CC
differential/JJ
expression/NN
,/,
which/WDT
was/VBD
measured/VBN
using/VBG
linear/JJ
regression/NN
,/,
revealing/VBG
a/DT
significant/JJ
correlation/NN
of/IN
cg15839448/NN
(/(
chr8:41285687/NN
)/)
(/(
p/NN
=/JJ
0.1E-9/CD
)/)
./.
====================
R/Bioconductor/NN
package/NN
methy/NN
Analysis/NN
was/VBD
used/VBN
to/TO
depict/VB
the/DT
chromosomal/JJ
location/NN
in/IN
relation/NN
to/TO
CGI/NN
,/,
along/IN
with/IN
the/DT
methylation/NN
beta-value/IN
,/,
as/IN
a/DT
heat/NN
map/VBP
(/(
Fig/NN
./.
====================
7/CD
)/)
,/,
confirming/VBG
the/DT
variation/NN
among/IN
probes/NNS
./.
====================
Aberrant/JJ
methylation/NN
patterns/NNS
of/IN
SFRP/NN
have/VBP
been/VBN
reported/VBN
not/RB
only/RB
in/IN
colorectal/JJ
cancers/NNS
but/CC
also/RB
in/IN
gastric/JJ
cancers/NNS
[/(
12/CD
]/)
,/,
breast/NN
cancers/NNS
[/(
10/CD
]/)
,/,
and/CC
pancreatic/JJ
cancers/NNS
[/(
13/CD
]/)
./.
====================
From/IN
TCGA/NN
,/,
we/PRP
downloaded/VBD
12/CD
matched/VBN
pairs/NNS
for/IN
each/DT
cancer/NN
of/IN
the/DT
following/VBG
organs/NNS
:/:
bladder/JJ
,/,
breast/NN
,/,
esophageal/JJ
,/,
kidney/NN
,/,
liver/NN
,/,
lung/NN
,/,
pancreas/NN
,/,
prostate/NN
,/,
stomach/DT
,/,
and/CC
uterine/JJ
corpus/NN
endometrium/NN
./.
====================
Except/IN
for/IN
liver/NN
and/CC
endometrial/JJ
cancers/NNS
,/,
the/DT
DNA/NN
methylation/NN
levels/NNS
of/IN
both/DT
SFRP1/NN
and/CC
SFRP2/NN
were/VBD
consistently/RB
higher/JJR
in/IN
cancers/NNS
than/IN
in/IN
the/DT
normal/JJ
counterparts/NNS
(/(
Fig/NN
./.
====================
8/CD
)/)
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
in/IN
colorectal/JJ
cancers/NNS
,/,
the/DT
mean/JJ
methylation/NN
M-value/NN
of/IN
the/DT
tumor/NN
samples/NNS
was/VBD
greater/JJR
than/IN
0/CD
./.
====================
While/IN
stomach/NN
cancers/NNS
(/(
STAD/NN
)/)
also/RB
showed/VBD
a/DT
mean/JJ
M/NN
of/IN
greater/JJR
than/IN
0/CD
,/,
the/DT
difference/NN
between/IN
the/DT
tumor/NN
and/CC
normal/JJ
sample/JJ
was/VBD
not/RB
as/IN
large/JJ
as/IN
in/IN
colorectal/JJ
cancers/NNS
./.
====================
In/IN
all/DT
other/JJ
cancers/NNS
,/,
the/DT
mean/JJ
M/NN
was/VBD
below/IN
0/CD
,/,
implying/VBG
marginal/JJ
hypermethylation/NN
at/IN
most/JJS
./.
====================
Survival/NN
analysis/NN
:/:
SFRP/NN
methylation/NN
in/IN
association/NN
with/IN
clinical/JJ
factors/NNS
====================
It/PRP
is/VBZ
well/RB
known/VBN
that/IN
the/DT
survival/NN
rate/NN
of/IN
colorectal/JJ
cancer/NN
is/VBZ
negatively/RB
correlated/VBD
with/IN
the/DT
tumor/NN
stage/NN
:/:
the/DT
higher/JJR
the/DT
stage/NN
,/,
the/DT
poorer/JJ
the/DT
survival/NN
./.
====================
We/PRP
confirmed/VBD
this/DT
trend/NN
in/IN
the/DT
expanded/VBN
dataset/NN
(/(
n/NN
=/JJ
419/CD
)/)
./.
====================
Stages/NNS
IIA/NN
and/CC
IIB/NN
were/VBD
merged/VBN
into/IN
stage/NN
II/CD
,/,
and/CC
similarly/RB
,/,
stages/NNS
IIIA/NN
,/,
IIIB/NN
,/,
and/CC
IIIC/NN
were/VBD
merged/VBN
into/IN
stage/NN
III/CD
./.
====================
The/DT
Kaplan-Meier/NN
survival/NN
curves/VBZ
showed/VBD
,/,
as/IN
expected/VBN
,/,
lower/JJR
survival/NN
for/IN
higher/JJR
stages/NNS
(/(
Fig/NN
./.
====================
9/CD
)/)
./.
====================
The/DT
Cox/NN
regression/NN
analyses/NNS
also/RB
indicated/VBD
a/DT
significant/JJ
association/NN
of/IN
stage/NN
IV/CD
with/IN
survival/NN
rate/NN
(/(
mean/JJ
hazard/JJ
ratio/NN
6.083/CD
)/)
(/(
95/CD
%/NN
confidence/NN
interval/JJ
[/(
CI/NN
]/)
,/,
1.778/CD
to/TO
20.812/CD
;/:
p/NN
=/JJ
0.004/CD
)/)
(/(
Table/JJ
4/CD
)/)
./.
====================
Upon/IN
confirming/VBG
the/DT
anticipated/JJ
survival/NN
trends/VBZ
by/IN
stage/NN
in/IN
the/DT
expanded/VBN
dataset/NN
,/,
we/PRP
tested/VBD
whether/IN
the/DT
methylation/NN
level/NN
of/IN
SFRP1/NN
correlated/VBD
with/IN
the/DT
survival/NN
rate/NN
./.
====================
Among/IN
the/DT
four/CD
methylation/NN
probes/NNS
,/,
cg15839448/NN
was/VBD
chosen/NN
,/,
as/IN
its/PRP$
methylation/NN
level/NN
showed/VBD
the/DT
most/JJS
consistent/JJ
correlation/NN
with/IN
the/DT
expression/NN
level/NN
of/IN
SFRP1/NN
./.
====================
In/IN
order/NN
to/TO
separate/VB
the/DT
samples/NNS
into/IN
two/CD
groups/NNS
that/IN
showed/VBD
a/DT
survival/NN
difference/NN
according/VBG
to/TO
SFRP1/NN
methylation/NN
beta-values/NNS
,/,
we/PRP
used/VBD
maximally/RB
selected/VBN
rank/VBP
statistics/NNS
,/,
implemented/VBD
in/IN
R/NN
(/(
the/DT
maxstat/JJ
package/NN
)/)
,/,
yielding/VBG
the/DT
cutoff/JJ
point/NN
(/(
beta-value/IN
=/JJ
0.598/CD
)/)
(/(
Fig/NN
./.
====================
10A/CD
)/)
./.
====================
Similarly/RB
,/,
cg23207990/NN
was/VBD
chosen/NN
for/IN
SFRP2/NN
,/,
yielding/VBG
the/DT
cutoff/JJ
point/NN
(/(
beta-value/JJ
=/JJ
0.713/CD
)/)
(/(
Fig/NN
./.
====================
10B/CD
)/)
./.
====================
The/DT
group/NN
with/IN
highly/RB
methylated/VBN
SFRP1/NN
showed/VBD
poorer/JJ
survival/NN
than/IN
the/DT
other/JJ
group/NN
(/(
p/NN
=/JJ
0.0181/CD
)/)
(/(
Fig/NN
./.
====================
11A/NN
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
SFRP2/NN
methylation/NN
did/VBD
not/RB
exhibit/VB
a/DT
significant/JJ
relationship/NN
(/(
p/NN
=/JJ
0.107/CD
)/)
(/(
Fig/NN
./.
====================
11B/NN
)/)
./.
====================
The/DT
corresponding/JJ
hazard/JJ
ratios/NNS
from/IN
the/DT
Cox/NN
regression/NN
analysis/NN
were/VBD
1.93/CD
(/(
95/CD
%/NN
CI/NN
,/,
1.119/CD
to/TO
3.329/CD
)/)
and/CC
1.703/CD
(/(
95/CD
%/NN
CI/NN
,/,
0.892/CD
to/TO
3.25/CD
)/)
for/IN
SFRP1/NN
and/CC
SFRP2/NN
,/,
respectively/RB
(/(
Table/JJ
4/CD
)/)
./.
====================
As/IN
higher/JJR
tumor/NN
stage/NN
shows/VBZ
a/DT
higher/JJR
risk/NN
rate/NN
in/IN
the/DT
cumulative/JJ
hazard/JJ
curve/NN
(/(
Fig/NN
./.
====================
12A/NN
)/)
,/,
higher/JJR
SFRP1/NN
methylation/NN
also/RB
increases/VBZ
the/DT
risk/NN
rate/NN
(/(
Fig/NN
./.
====================
12B/NN
)/)
./.
====================
In/IN
conclusion/NN
,/,
hypermethylation/NN
of/IN
SFRP/NN
genes/NNS
has/VBZ
been/VBN
linked/VBN
to/TO
the/DT
downregulation/NN
of/IN
their/PRP$
expression/NN
in/IN
colorectal/JJ
cancers/NNS
[/(
11/CD
]/)
./.
====================
Here/RB
,/,
we/PRP
confirm/VBP
it/PRP
using/VBG
independent/JJ
TCGA/NN
datasets/NNS
./.
====================
The/DT
evidence/NN
was/VBD
stronger/JJR
for/IN
SFRP1/NN
but/CC
only/RB
marginal/JJ
for/IN
SFRP2/NN
./.
====================
We/PRP
also/RB
demonstrate/VBP
that/IN
promoter/NN
hypermethylation/NN
of/IN
SFRP1/NN
is/VBZ
linked/VBN
to/TO
poor/JJ
survival/NN
of/IN
colorectal/JJ
cancer/NN
patients/NNS
./.
====================
Scatterplot/NN
of/IN
differential/JJ
methylation/NN
versus/CC
differential/JJ
expression/NN
./.
====================
A/DT
total/JJ
of/IN
27,578/CD
methylation/NN
probes/NNS
are/VBP
plotted/VBN
in/IN
grey/JJ
,/,
while/IN
those/DT
probes/NNS
showing/VBG
downregulated/VBD
expression/NN
by/IN
4-fold/JJ
or/CC
more/RBR
(/(
Î”/NNP
expression/NN
</JJR
-2/CD
)/)
and/CC
methylation/NN
value/NN
(/(
M/NN
value/NN
)/)
change/NN
of/IN
+1/CD
or/CC
more/RBR
are/VBP
plotted/VBN
as/IN
red/JJ
points/NNS
./.
====================
Negative/JJ
correlation/NN
between/IN
gene/NN
expression/NN
and/CC
DNA/NN
methylation/NN
in/IN
31/CD
selected/VBN
genes/NNS
./.
====================
Each/DT
circle/NN
represents/VBZ
a/DT
sample/JJ
./.
====================
Wnt/NN
signaling/NN
pathway/NN
from/IN
Kyoto/NN
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
(/(
SFRP/NN
genes/NNS
are/VBP
in/IN
red/JJ
box/NN
)/)
./.
====================
Heat/NN
map/VBP
of/IN
WNT2/NN
and/CC
SFRP1/NN
in/IN
the/DT
discovery/NN
dataset/NN
./.
====================
The/DT
12/CD
samples/NNS
on/IN
the/DT
left/NN
are/VBP
normal/JJ
,/,
while/IN
the/DT
12/CD
samples/NNS
on/IN
the/DT
right/JJ
are/VBP
tumors/NNS
./.
====================
Wilcoxon/JJ
rank-sum/NN
test/NN
with/IN
Wnt/NN
signaling-related/JJ
genes/NNS
and/CC
the/DT
others/NNS
./.
====================
Three/CD
Wnt/NN
signaling/NN
pathway/NN
genes/NNS
,/,
SFRP1/NN
(/(
-17.76/CD
)/)
,/,
SFRP2/NN
(/(
-5.98/CD
)/)
,/,
and/CC
WNT2/NN
(/(
-13.84/CD
)/)
,/,
are/VBP
marked/JJ
by/IN
red/JJ
ticks/NNS
in/IN
the/DT
rug/NN
plot/NN
./.
====================
Differential/JJ
methylation/NN
in/IN
four/CD
SFRP1/NN
probes/NNS
(/(
tumor/NN
,/,
166/CD
;/:
normal/JJ
,/,
37/CD
)/)
./.
====================
Methylation/NN
heat/NN
map/VBP
of/IN
four/CD
SFRP1/NN
probes/NNS
./.
====================
SFRP1/NN
is/VBZ
marked/JJ
by/IN
a/DT
vertical/JJ
red/JJ
line/NN
in/IN
the/DT
ideogram/NN
of/IN
chromosome/NN
8/CD
,/,
while/IN
tracks/NNS
of/IN
CpG/NN
islands/NNS
and/CC
exon-intron/NN
structures/NNS
are/VBP
shown/VBN
./.
====================
The/DT
heat/NN
map/VBP
in/IN
methylation/NN
profile/NN
track/VBP
shows/VBZ
the/DT
methylation/NN
beta-values/NNS
of/IN
the/DT
four/CD
probes/NNS
(/(
cg06166767/NN
,/,
cg13398291/NN
,/,
cg15839448/CD
,/,
and/CC
cg22418909/NN
from/IN
left/NN
to/TO
right/JJ
)/)
./.
====================
Each/DT
row/NN
of/IN
the/DT
heat/NN
map/VBP
represents/VBZ
one/CD
of/IN
the/DT
samples/NNS
,/,
which/WDT
are/VBP
ordered/VBN
as/IN
shown/VBN
by/IN
the/DT
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
sample/NN
codes/VBZ
./.
====================
The/DT
last/JJ
two/CD
digits/NNS
of/IN
the/DT
TCGA/NN
sample/NN
codes/VBZ
represent/VBP
sample/JJ
types/NNS
:/:
``/CD
01/CD
''/CD
for/IN
tumor/NN
sample/NN
and/CC
``/NN
11/CD
''/NN
for/IN
matched/VBN
normal/JJ
./.
====================
Comparison/NN
of/IN
SFRP1/NN
(/(
left/NN
panel/NN
)/)
and/CC
SFRP2/NN
(/(
right/JJ
panel/NN
)/)
methylation/NN
among/IN
11/CD
cancer/NN
types/NNS
./.
====================
Each/DT
cancer/NN
type/NN
is/VBZ
shown/VBN
by/IN
the/DT
boxplot/NN
of/IN
normal/JJ
samples/NNS
,/,
followed/VBN
by/IN
that/DT
of/IN
tumor/NN
samples/NNS
./.
====================
Colorectal/JJ
cancers/NNS
are/VBP
enclosed/VBN
by/IN
red/JJ
boxes/NNS
./.
====================
Survival/NN
curves/NNS
by/IN
colorectal/JJ
cancer/NN
stage/NN
./.
====================
SFRP/NN
gene/NN
cutoff/JJ
points/NNS
by/IN
maximally/RB
selected/VBN
rank/VBP
statistic/JJ
./.
====================
The/DT
cutoff/JJ
points/NNS
are/VBP
marked/JJ
by/IN
vertical/JJ
dotted/JJ
lines/NNS
at/IN
0.598/CD
and/CC
0.713/CD
for/IN
SFRP1/NN
(/(
A/NN
)/)
and/CC
SFRP2/NN
(/(
B/NN
)/)
,/,
respectively/RB
./.
====================
Survival/NN
curves/NNS
of/IN
SFRP1/NN
(/(
A/NN
)/)
and/CC
SFRP2/NN
(/(
B/NN
)/)
by/IN
methylation/NN
beta-values/NNS
./.
====================
X-axis/NN
represents/VBZ
survival/NN
time/NN
in/IN
days/NNS
./.
====================
Cumulative/JJ
hazard/JJ
curve/NN
of/IN
colorectal/JJ
cancer/NN
by/IN
stage/NN
(/(
A/NN
)/)
and/CC
SFRP1/NN
methylation/NN
(/(
B/NN
)/)
values/NNS
./.
====================
X-axis/NN
represents/VBZ
survival/NN
time/NN
in/IN
days/NNS
./.
====================
Differentially/RB
hypermethylated/JJ
and/CC
downregulated/VBD
genes/NNS
====================
Differentially/RB
hypermethylated/JJ
and/CC
downregulated/VBD
genes/NNS
====================
Differentially/RB
hypermethylated/JJ
and/CC
downexpressed/VBD
genes/NNS
====================
Hazard/JJ
ratio/NN
of/IN
colorectal/JJ
patients/NNS
by/IN
tumor/NN
stage/NN
and/CC
SFRP/NN
methylation/NN
status/NN
====================
